GILEAD SCIENCES, INC.
GILD · XNASCIK 882095fmd_00F0D2C45K8MQ2K0S75TM55VSFManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2007 to Sep 30, 2026, 75 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 30,390 | 26,107 | 22,127 | 22,449 | 24,689 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 |
| Cost of revenue | 4,261 | 4,371 | 4,853 | 4,675 | 4,572 | 6,601 | 5,657 | 6,498 | 6,251 | 6,234 |
| Gross profit | 26,129 | 21,736 | 17,274 | 17,774 | 20,117 | 20,704 | 21,624 | 20,618 | 22,503 | 23,209 |
| Research and development | 5,098 | 3,734 | 3,920 | 4,055 | 4,927 | 4,601 | 4,977 | 5,718 | 5,907 | 5,799 |
| Selling, general and administrative | 3,398 | 3,878 | 4,056 | 4,381 | 5,151 | 5,246 | 5,673 | 6,090 | 6,091 | 5,774 |
| Operating income | 17,633 | 14,124 | 8,200 | 4,287 | 4,071 | 9,918 | 7,330 | 7,605 | 1,662 | 10,022 |
| Interest expense | 964 | 1,118 | 1,077 | 995 | 984 | 1,001 | 935 | 944 | 977 | 1,024 |
| Other non-operating income (expense) | 428 | 523 | 676 | 1,868 | (1,418) | (639) | (581) | 198 | 6 | 798 |
| Income before taxes | 17,097 | 13,529 | 7,799 | 5,160 | 1,669 | 8,278 | 5,814 | 6,859 | 690 | 9,796 |
| Income tax expense | 3,609 | 8,885 | 2,339 | (204) | 1,580 | 2,077 | 1,248 | 1,247 | 211 | 1,286 |
| Net income from continuing operations | 13,488 | 4,644 | 5,460 | 5,364 | 89 | 6,201 | 4,566 | 5,612 | 479 | 8,510 |
| Net income | 13,501 | 4,628 | 5,455 | 5,386 | 123 | 6,225 | 4,592 | 5,665 | 480 | 8,510 |